Barinthus Biotherapeutics (BRNS) to Release Earnings on Thursday

Key Points

• Barinthus Biotherapeutics is set to announce its quarterly earnings on Thursday, August 14th, with analysts predicting an earnings loss of ($0.33) per share for Q2 2025.
• The company previously reported an earnings loss of ($0.49) per share for the last quarter, which was below the consensus estimate by ($0.15).
• Barinthus Biotherapeutics has a current market cap of $52.85 million and its stock is trading at $1.31, having seen a one-year low of $0.64 and a high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.23). On average, analysts expect Barinthus Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Barinthus Biotherapeutics Price Performance

BRNS traded down $0.11 during trading on Friday, reaching $1.34. 25,082 shares of the stock traded hands, compared to its average volume of 3,845,176. The stock has a market cap of $54.06 million, a price-to-earnings ratio of -0.77 and a beta of -0.73. Barinthus Biotherapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.92. The stock's 50-day simple moving average is $1.17 and its two-hundred day simple moving average is $1.01.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.